• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot ) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: A pilot study.

作者信息

Nakajima Yuto, Takami Eisuke, Nakano Hirotoshi, Nogami Keiji

机构信息

Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan.

Advanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Nara, Japan.

出版信息

Haemophilia. 2022 Sep;28(5):e149-e152. doi: 10.1111/hae.14650. Epub 2022 Aug 10.

DOI:10.1111/hae.14650
PMID:35947585
Abstract
摘要

相似文献

1
In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot ) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: A pilot study.血友病A伴抑制剂患者及获得性血友病A患者中血浆源性因子VIIa/X产品（拜科妥）与艾美赛珠单抗共同存在时整体凝血潜能的体外评估：一项初步研究
Haemophilia. 2022 Sep;28(5):e149-e152. doi: 10.1111/hae.14650. Epub 2022 Aug 10.
2
Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India.低剂量艾美赛珠单抗对血友病A患者的预防治疗：一项来自印度的初步研究。
Haemophilia. 2023 May;29(3):931-934. doi: 10.1111/hae.14785. Epub 2023 Apr 8.
3
Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.转换为艾美赛珠单抗：一项针对患有抑制剂的甲型血友病患者的前瞻性监测研究。
Haemophilia. 2023 Jan;29(1):348-351. doi: 10.1111/hae.14685. Epub 2022 Oct 31.
4
Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.依库珠单抗对人工添加因子 VIII 的血浆标本和有抑制物的血友病 A 患者样本的 APTT、一步法及显色法检测因子 VIII 的影响。
Haemophilia. 2020 May;26(3):536-542. doi: 10.1111/hae.13990. Epub 2020 Apr 6.
5
Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.实验室凝血检测和艾美赛珠单抗治疗：英国血友病中心医生组织指南。
Haemophilia. 2020 Jan;26(1):151-155. doi: 10.1111/hae.13903. Epub 2019 Dec 20.
6
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.人源化双特异性抗体在血友病 A 中模拟因子 VIII 的功能。
N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769.
7
Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy.使用四种不同试剂对重度A型血友病患者进行的依美珠单抗分析评估：从基线到维持治疗的浓度
Haemophilia. 2023 Jan;29(1):374-376. doi: 10.1111/hae.14703. Epub 2022 Nov 29.
8
Major surgery management in patients with haemophilia A and inhibitors on emicizumab prophylaxis without global coagulation monitoring.在接受emicizumab预防治疗且无全面凝血监测的甲型血友病和抑制剂患者中的大手术管理
Br J Haematol. 2020 May;189(3):e100-e103. doi: 10.1111/bjh.16512. Epub 2020 Feb 22.
9
Emicizumab for the treatment of haemophilia A: a narrative review.依库珠单抗治疗 A 型血友病：一篇叙述性综述。
Blood Transfus. 2019 May;17(3):223-228. doi: 10.2450/2019.0026-19.
10
A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.一项关于emicizumab预防在接受小手术的有或无FVIII抑制剂的A型血友病患者中的IV期、多中心、开放标签研究。
Haemophilia. 2022 Jul;28(4):e105-e108. doi: 10.1111/hae.14574. Epub 2022 May 5.

引用本文的文献

1
Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review.依库珠单抗治疗获得性血友病患者的疗效：系统评价。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241298661. doi: 10.1177/10760296241298661.
2
Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates.在emicizumab和活化凝血酶原复合物浓缩剂同时存在的情况下活化蛋白C抵抗
Res Pract Thromb Haemost. 2024 Jun 18;8(4):102479. doi: 10.1016/j.rpth.2024.102479. eCollection 2024 May.
3
NXT007-mediated hemostatic potential is suppressed by activated protein C-catalyzed inactivation of activated factor V.
NXT007介导的止血潜能被活化蛋白C催化的活化因子V失活所抑制。
Res Pract Thromb Haemost. 2023 Nov 23;8(1):102271. doi: 10.1016/j.rpth.2023.102271. eCollection 2024 Jan.